

**Note to readers with disabilities:** *EHP* strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in *EHP* articles may not conform to [508 standards](#) due to the complexity of the information being presented. If you need assistance accessing journal content, please contact [ehp508@niehs.nih.gov](mailto:ehp508@niehs.nih.gov). Our staff will work with you to assess and meet your accessibility needs within 3 working days.

### **Supplemental Material**

#### **Case–Cohort Study of the Association between PFAS and Selected Cancers among Participants in the American Cancer Society’s Cancer Prevention Study II LifeLink Cohort**

Andrea Winquist, James M. Hodge, W. Ryan Diver, Juan L. Rodriguez, Alyssa N. Troeschel, Johnni Daniel, and Lauren R. Teras

#### **Table of Contents**

**Table S1.** Definitions used for cancer histologic subtypes using International Classification of Disease for Oncology (ICD-O) histology codes.

**Table S2.** Comparison of characteristics of study participants for the Overall CPS-II LifeLink cohort (n=39,371), the CPS-II LifeLink Cohort Meeting Case-cohort Study Inclusion Criteria (n=29,985), and participants selected for the sub-cohort (n=1000 selected, 999 with PFAS serum measurements), Case-cohort study of association between PFAS and selected cancers among participants in the Cancer Prevention II LifeLink cohort, 1998-2015.

**Table S3.** Characteristics of sub-cohort participants and participants with incident cancers, Case-cohort study of association between PFAS and selected cancers among participants in the Cancer Prevention II LifeLink cohort, 1998-2015.

**Table S4.** Results of Quality Control analysis using samples run with study samples, Case-cohort study of association between PFAS and selected cancers among participants in the Cancer Prevention II LifeLink cohort, 1998-2015.

**Table S5.** Percentage of samples with PFAS detections in the subcohort, Case-cohort study of association between PFAS and selected cancers among participants in the Cancer Prevention II LifeLink cohort, 1998-2015.

**Table S6.** Distribution of PFAS serum concentrations among subcohort participants (ng/ml, values below the limit of detection were imputed as the limit of detection divided by the square root of 2), Case-cohort study of association between PFAS and selected cancers among participants in the Cancer Prevention II LifeLink cohort, 1998-2015.

**Table S7.** Spearman correlation coefficients for correlations between PFAS serum concentrations among subcohort members, Case-cohort study of association between PFAS and selected cancers among participants in the Cancer Prevention II LifeLink cohort, 1998-2015.

**Table S8.** PFAS Distributions (ng/ml) in the subcohort by categories of covariates, using values with values below the limit of detection imputed as the limit of detection divided by the square root of 2, Case-cohort study of association between PFAS and selected cancers among participants in the Cancer Prevention II LifeLink cohort, 1998-2015.

**Table S9.** Results from primary models for overall cancer sites, Case-cohort study of association between PFAS and selected cancers among participants in the Cancer Prevention II LifeLink cohort, 1998-2015.

**Table S10.** Results from primary models for histologic subtypes, Case-cohort study of association between PFAS and selected cancers among participants in the Cancer Prevention II LifeLink cohort, 1998-2015.

**Table S11.** Ratio of the number of cases to the number of parameters in various models, Case-cohort study of association between PFAS and selected cancers among participants in the Cancer Prevention II LifeLink cohort, 1998-2015.

**Figure S1.** Timeline of study participant recruitment, Case-cohort study of association between PFAS and selected cancers among participants in the Cancer Prevention II LifeLink cohort, 1998-2015.

**Figure S2.** Hematologic sub-groups considered, Case-cohort study of association between PFAS and selected cancers among participants in the Cancer Prevention II LifeLink cohort, 1998-2015.

**Figure S3.** Box plots of PFAS serum concentrations among subcohort participants and participants with incident cancers (ng/ml), Case-cohort study of association between PFAS and selected cancers among participants in the Cancer Prevention II LifeLink cohort, 1998-2015.

**Figure S4.** Hazard ratios and 95% confidence intervals from primary models for overall cancer site groups per doubling of PFAS concentrations (using  $\log_2$ -transformed measures) [solid circles] and for quartiles defined among cases relative to quartile 1 [open circles], Case-cohort study of association between PFAS and selected cancers among participants in the Cancer Prevention II LifeLink cohort, 1998-2015.

**Figure S5.** Hazard ratios and 95% confidence intervals from primary models for histologic sub-groups for bladder and kidney cancer per doubling of PFAS concentrations (using  $\log_2$ -transformed measures) [solid circles] and for quartiles defined among cases relative to quartile 1 [open circles], Case-cohort study of association between PFAS and selected cancers among participants in the Cancer Prevention II LifeLink cohort, 1998-2015.

**Figure S6.** Hazard ratios and 95% confidence intervals from primary models for histologic subgroups for hematologic malignancies per doubling of PFAS concentrations (using log<sub>2</sub>-transformed measures) [solid circles] and for quartiles defined among cases relative to quartile 1 [open circles], Case-cohort study of association between PFAS and selected cancers among participants in the Cancer Prevention II LifeLink cohort, 1998-2015.